Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Xeris Pharmaceuticals Inc (XERS)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Xeris Pharmaceuticals Inc since year 2005.
Table 2 shows the detailed insider transactions of Xeris Pharmaceuticals Inc since 2005.
The reporting company's ticker symbol is XERS. The reporting company's CIK number is 1346302.
The total value of stock buying since 2005 is $29,738,620.
The total value of stock sales since 2005 is $2,548,771.
The total value of stock option exercises since 2005 is $18,706.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2019-04-11||Prestrelski Steven (Chief Scientific Officer)||Sale||10,000||9.56||95,650|
|2019-03-11||Edick Paul R (See Remarks)||Buy||30,000||9.12||273,600|
|2019-02-19||Johnson Kenneth Erland (See Remarks)||Buy||1,000||10.00||10,000|
|2019-02-19||Hecht Beth (See Remarks)||Buy||2,500||10.00||25,000|
|2019-02-19||Deutsch Barry M. (See Remarks)||Buy||5,000||10.00||50,000|
|2019-02-11||Deerfield Private Design Fund Iii, L.p.||Sale||1,351||15.00||20,265|
|2019-02-08||Deerfield Private Design Fund Iii, L.p.||Sale||5,890||15.11||88,986|
|2019-02-07||Deerfield Private Design Fund Iii, L.p.||Sale||9,409||15.00||141,135|
|2019-02-06||Deerfield Private Design Fund Iii, L.p.||Sale||400||15.00||6,000|
|2019-02-05||Deerfield Private Design Fund Iii, L.p.||Sale||4,998||15.07||75,309|
|2019-01-29||Deerfield Private Design Fund Iii, L.p.||Sale||6,210||15.14||94,025|
|2019-01-28||Deerfield Private Design Fund Iii, L.p.||Sale||828||15.00||12,420|
|2019-01-25||Deerfield Private Design Fund Iii, L.p.||Sale||76,820||15.08||1,158,291|
|2019-01-24||Deerfield Private Design Fund Iii, L.p.||Sale||5,425||15.04||81,564|
|2019-01-23||Deerfield Private Design Fund Iii, L.p.||Sale||32,199||16.35||526,389|
|2019-01-11||Prestrelski Steven (Chief Scientific Officer)||Sale||2,300||.00||0|
|2018-12-26||Prestrelski Steven (Chief Scientific Officer)||Sale||15,720||15.82||248,737|
|2018-12-24||Prestrelski Steven (Chief Scientific Officer)||Option Ex||15,720||1.19||18,706|
|2018-06-25||Palmetto Partners 2015, Lp (10% Owner)||Buy||150,000||15.00||2,250,000|
|2018-06-25||Deerfield Private Design Fund Iii, L.p.||Buy||750,000||15.00||11,250,000|
Insider trading activities including stock purchases, stock sales, and option exercises of XERS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Xeris Pharmaceuticals Inc (symbol XERS, CIK number 1346302) see the Securities and Exchange Commission (SEC) website.